How to create a winning joint clinical assessment (JCA) dossier in 90 days?

Numerus and SKC launch joint solution JCA90

Mon, 2023 / 10 / 16
The clock is ticking. From 2025 onwards all ATMPs and oncological drugs seeking access to the European market will have to submit a European Joint Clinical Assessment (JCA) dossier.

With the end of EUnetHTA21, most of the fundamental processes are in place with one thing becoming clear: following the finalisation of the PICO scoping process, pharmaceutical companies will only have 90 days to produce the final JCA dossier.

To perfectly orchestrate all workstreams into this tight timeline, one needs robust, convincing evidence and a comprehensive strategy that can anticipate and prioritise likely scenarios. Only through such an approach can one achieve the desired national price. That is why Numerus and SKC have combined their expertise in the collaborative solution - JCA90. With JCA90, we support our clients in mastering EU HTA.

About the author

Ihre Ansprechpartnerin Dipl.-Kauffrau Heike Kielhorn-Schönermark
Dipl.-Kauffrau Heike Kielhorn-Schönermark
Founder and Managing Director
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18

EU HTA: European Health Technology Assessment (JCA)

Achieve planning security: With us you can align your projects and your resource planning comprehensively and at an early stage on EU HTA and its implications for market access.
to the top